Misra Sunita N, Sperling Michael R, Rao Vikram R, Peters Jurriaan M, Penovich Patricia, Wheless James, Hogan R Edward, Davis Charles S, Carrazana Enrique, Rabinowicz Adrian L
Formerly of Neurelis, Inc., 3430 Carmel Mountain Rd, Ste 300, San Diego, CA 92121, USA.
Thomas Jefferson University, 909 Walnut St., Philadelphia, PA 19107, USA.
Epilepsy Behav Rep. 2024 Jan 2;25:100644. doi: 10.1016/j.ebr.2024.100644. eCollection 2024.
For acute treatment of seizure clusters in patients with epilepsy, intranasal administration of acute seizure therapies has been shown to provide accessibility and ease of use to care partners as well as the potential for self-administration by patients. Diazepam nasal spray (Valtoco®) was approved by the US Food and Drug Administration for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) in patients with epilepsy aged ≥6 years. Self-administration consistent with the prescribing information is feasible and was reported by a subgroup of patients (n = 27 of 163) in a long-term phase 3 safety study. Data regarding self-administration among these patients with seizure clusters are examined here to explore the safety profiles and measures of effectiveness, as well as the quality of life of those who self-treated. In addition, this focused look at patients who self-administered diazepam nasal spray may offer some insights into the characteristics of patients who may be appropriate for self-administration.
对于癫痫患者癫痫发作丛集的急性治疗，已证明经鼻给予急性癫痫治疗药物可为护理人员提供便利且易于使用，患者也有自行给药的可能。地西泮鼻喷雾剂（Valtoco®）已获美国食品药品监督管理局批准，用于急性治疗≥6岁癫痫患者的间歇性、刻板性频繁癫痫发作（即癫痫发作丛集、急性重复性癫痫发作）。在一项长期3期安全性研究中，一组患者（163例中的27例）报告称，按照处方信息自行给药是可行的。本文研究了这些癫痫发作丛集患者的自行给药数据，以探讨安全性、有效性指标以及自行治疗患者的生活质量。此外，对自行使用地西泮鼻喷雾剂患者的重点观察，可能会为适合自行给药的患者特征提供一些见解。
